Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Natco Pharma, Celgene ink pact for cancer treatment drug Lenalidomide

Ruchika Sharma11 July 2020 12:47 PM IST

Lenalidomide is used to treat various types of cancers.

Unichem Labs gets USFDA nod to Baclofen Tablets for spasticity relief

Ruchika Sharma11 July 2020 11:08 AM IST

Baclofen Tablets are indicated for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief...

Takeda launches gastrointestinal drug Vedolizumab in India

Ruchika Sharma11 July 2020 9:30 AM IST

Kynteles is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn's Disease (CD).

Ensure production, adequate stock of methylprednisolone, heparin, dexamethasone: NPPA directs pharma cos

Ruchika Sharma10 July 2020 4:49 PM IST

New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has directed State Drug Controllers (SDCs) to...

Merck, Foghorn enter over Rs 3197 crore deal to Discover, Develop Novel Oncology Therapeutics

Ruchika Sharma10 July 2020 3:29 PM IST

Cambridge: Foghorn Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in...

COVID-19: Panacea Biotec sees production of 1 billion doses of vaccine candidate in 2022

Ruchika Sharma10 July 2020 3:21 PM IST

The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an...

Several short, long-term efforts required to revive pharma ancillary industry: IPA

Ruchika Sharma10 July 2020 12:13 PM IST

For the revival of the ancillary industry, several short-term and long-term efforts are required to be made by all stakeholders, a report on the theme...

Strides Pharma gets USFDA nod to headache drugs Acetaminophen, Caffeine, others

Ruchika Sharma10 July 2020 11:40 AM IST

Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is indicated for the relief of the symptom complex of tension (or muscle...

Rossari Biotech to launch Rs 500-crore IPO soon

Ruchika Sharma10 July 2020 9:15 AM IST

Going by the draft papers, Rossari Biotech's IPO comprises fresh issuance of shares to the tune of Rs 150 crore and sale of more than 1 crore equity...

Mylan recalls one lot of injectable daptomycin over presence of particulate matter

Ruchika Sharma9 July 2020 5:18 PM IST

Daptomycin for injection is an injectable antibacterial indicated for the treatment of complicated skin and skin structure infections (cSSSI) and...

Unacademy acquires NEET preparation platform PrepLadder for Rs 374.6 crore

Ruchika Sharma9 July 2020 3:48 PM IST

The acquisition will help Unacademy expand its annual revenues by 15 percent, it said.

Lupin recalls Metformin Hydrochloride ER tablets in US over presence of NDMA Impurity

Ruchika Sharma9 July 2020 1:35 PM IST

Baltimore: Drug major Lupin Ltd recently said it is voluntarily recalling its diabetes treatment drug Metformin Hydrochloride extended-release...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok